Renal fibrosis is the common pathological basis for the progressive development of chronic kidney disease (CKD) caused by various etiologies. It is characterized by the persistent deposition of extracellular matrix, leading to renal tissue damage and impaired renal function, and ultimately progressing to kidney failure. Current clinical treatments for CKD mainly focus on managing the primary diseases, with no specific drugs targeting renal fibrosis. The pathogenesis of renal fibrosis is complex, and there are currently no drugs available to reverse it. A comprehensive overview of the pathogenesis of renal fibrosis, alongside a summary of current anti-fibrotic therapies, including some that are already used clinically to slow renal function progression, new drugs in clinical trials, and emerging targeted therapies, could provide new theoretical foundations and perspectives for the treatment of renal fibrosis.
肾纤维化是各种病因导致慢性肾病进行性发展的共同病理基础，以细胞外基质的持续沉积为特征，导致肾组织损伤和肾功能受损，最终进展为肾衰竭。目前慢性肾病的临床治疗措施主要针对其原发疾病，而无专门治疗肾纤维化的药物。肾纤维化的发病机制复杂，暂尚无可逆转肾纤维化的药物。概述肾纤维化的发病机制，总结目前包括部分已用于临床的延缓肾功能进展药物、临床试验中的新药和正在开发的靶向药的抗肾纤维化药物进展，可为肾纤维化的治疗提供新的理论依据和思路。.
Keywords: anti-renal fibrosis drugs; chronic kidney disease; renal fibrosis.